Fundraising FoxAligos Therapeutics
South San Francisco, US · Founded 2018 · 4 known investors
Find your way into Aligos Therapeutics
Sign up to see every warm intro you have to Aligos Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aligos Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
Founders & leadership
Aligos Therapeutics was founded in 2018 by Leonid Beigelman and Lawrence M. Blatt.
HA
Hardean AchneckChief Medical Officer2024–2026Hardean Achneck is a physician–scientist and dual US/EU-licensed biotech executive who served as Executive Vice President and Chief Medical Officer at Aligos Therapeutics. He previously held faculty positions as Assistant Professor of Surgery and Pathology at Duke University Medical Center and as Assistant Professor of Cardiovascular & Metabolic Disorders at Duke-National University of Singapore, and has led clinical development programs across liver diseases, infectious diseases, and rare diseases using siRNA, small-molecule, and antibody platforms.
BD
Brian DowdExecutive Vice President2019–2020Brian Dowd began his accounting career at Deloitte in Los Angeles before spending three decades in financial leadership roles at technology and life sciences companies, with experience in IPO preparation, private equity transactions, and financial infrastructure for clinical and preclinical research organizations.
JS
Julian SymonsExecutive Vice President, Chief Scientific OfficerJulian Symons holds a D.Phil. from the University of York and spent 13 years conducting academic research in immunology and virology at universities in Edinburgh, Sheffield, and Oxford before joining Roche in 1999, where he contributed to antiviral programs including the development of sofosbuvir and danoprevir for hepatitis C. He subsequently led virology activities at Alios Biopharma (acquired by Janssen/J&J in 2014) and served as Global R&D Leader for Respiratory Infections at Janssen before becoming Chief Scientific Officer of Aligos Therapeutics.
SM
Sushmita M. ChandaExecutive Vice President, Chief Development OfficerSushmita M. Chanda is Executive Vice President and Chief Development Officer of Aligos Therapeutics, a clinical-stage biotechnology company developing therapeutics for liver and viral diseases. She brings over 20 years of pharmaceutical industry experience in drug discovery, development, and safety assessment.
JH
Jim HassardEVP, Chief Commercial OfficerJim Hassard has held sales, marketing, and commercial leadership roles across North America, Europe, and emerging markets over a 30+ year career. He has managed P&L responsibility for pharmaceutical brands from launch through maturity and led commercial teams across multiple geographies including Canada, Portugal, Switzerland, and the United States.
DB
David B. SmithExecutive Vice President, Head of Chemical Operations
PM
Peter MoldtNamed on SEC filing
MY
Michael YiNamed on SEC filing
Investors · 4
Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco
How we know: Pivotal Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M
How we know: Roche Venture Fund's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$282.2M disclosed across 3 rounds · 2019–2025
▶$105MraisedFeb 2025 · 12 investors · BiotechnologyRule 506(b)
▶$105MraisedFeb 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bridget MartellDirector
- Julian SymonsExecutive Officer
- Margarita ChavezDirector
- K. Peter HirthDirector
- Heather PrestonDirector
- Lesley Ann CalhounExecutive Officer
- Lawrence M. BlattExecutive Officer, Director
- James ScopaDirector
- Hardean AchneckExecutive Officer
- Carole NuechterleinDirector
- Offering amount
- $105M
- Amount sold
- $105M
- Sales commissions
- $2.7M
- Placement agents
- Piper Sandler & Co., Jefferies LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.2MraisedNov 2023 · 11 investors · BiotechnologyRule 506(b)
▶$92.2MraisedNov 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lesley Ann CalhounExecutive Officer
- Bridget MartellDirector
- Jack NielsenDirector
- Leonid BeigelmanExecutive Officer, Director
- Lucinda QuanExecutive Officer
- Carole NuechterleinDirector
- Julian SymonsExecutive Officer
- Lawrence BlattExecutive Officer, Director
- Matthew McClureExecutive Officer
- James ScopaDirector
- Peter HirthDirector
- Offering amount
- $92.2M
- Amount sold
- $92.2M
- Sales commissions
- $5.5M
- Placement agents
- PIPER SANDLER & CO.
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedJan 2020 · 38 investors · BiotechnologyRule 506(b)
▶$85MraisedJan 2020 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HirthDirector
- Carole NeuchterleinDirector
- Jack NielsenDirector
- Peter MoldtDirector
- Sushmita ChandaExecutive Officer
- Julian SymonsExecutive Officer
- Kathleen GlaubDirector
- Brian DowdExecutive Officer
- Lucinda QuanExecutive Officer
- Leonid BeigelmanExecutive Officer, Director
- Lawrence BlattExecutive Officer, Director
- Michael YiDirector
- Tom WoiwodeDirector
- John FryExecutive Officer
- Offering amount
- $125M
- Amount sold
- $85M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Aligos Therapeutics went on to found or lead other companies.
Related companies · 2
Apogee TherapeuticsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Aligos Therapeutics.
Frequently asked questions
- What does Aligos Therapeutics do?
- Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
- Who founded Aligos Therapeutics?
- Aligos Therapeutics was founded by Leonid Beigelman, Lawrence M. Blatt in 2018.
- Who are Aligos Therapeutics's investors?
- Aligos Therapeutics's investors include Pivotal Life Sciences, Roche Venture Fund, Wellington Management, Vivo Capital.
- How much funding has Aligos Therapeutics raised?
- Aligos Therapeutics has disclosed $282.2M raised across 3 rounds.
- Where is Aligos Therapeutics headquartered?
- Aligos Therapeutics is headquartered in South San Francisco, US.